Serum bilirubin and the risk of hypertension

International Journal of Epidemiology

Volumn 44, Issue 1, 2015, Pages 142-152

  Wang, Lina ^a   Bautista, Leonelo E ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antioxidants; Bilirubin; Blood pressure; Direct acyclic graphs; Multiple imputation; NHANES; Reactive oxygen species; Sensitivity analysis

Indexed keywords

ANTIHYPERTENSIVE AGENT; BILIRUBIN; CREATININE; URIC ACID;

ANTIOXIDANT; BIOAVAILABILITY; BLOOD; CARDIOVASCULAR DISEASE; PLASMA; RISK FACTOR; SENSITIVITY ANALYSIS;

ABDOMINAL OBESITY; ADULT; AFRICAN AMERICAN; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; AGE; BLOOD; BLOOD PRESSURE; EPIDEMIOLOGY; HEALTH BEHAVIOR; NUTRITION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; REPRODUCIBILITY; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS;

AGE FACTORS; BILIRUBIN; BLOOD PRESSURE; CONFOUNDING FACTORS (EPIDEMIOLOGY); HEALTH BEHAVIOR; HUMANS; HYPERTENSION; NUTRITION SURVEYS; OXIDATIVE STRESS; PREVALENCE; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84924594520     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyu242     Document Type: Article

References (107)

1. Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2224-60.
2. Rodrigues C, Rocha S, Nascimento H et al. Bilirubin levels and redox status in a young healthy population. Acta Haematol 2013;130: 57-60.
3. Bélanger S, Lavoie JC, Chessex P. Influence of bilirubin on the antioxidant capacity of plasma in newborn infants. Neonatology 1997;71: 233-38.
4. Vítek L, Jirsa M Jr, Brodanová M et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;160: 449-56.
5. Lin J-P, O'Donnell CJ, Schwaiger JP et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114: 1476-81.
6. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995;41: 1504-08.
7. Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol 2003;91: 485-88.
8. Djoussé L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87: 1196-200.
9. Pflueger A, Croatt AJ, Peterson TE et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005;288: F552-58.
10. Zucker SD, Qin X, Rouster SD et al. Mechanism of indinavirinduced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001;98: 12671-76.
11. Vera T, Granger JP, Stec DE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II- dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 2009;297: R738-43.
12. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997;131: 107-13.
13. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999;12: 673-81.
14. Chin HJ, Song YR, Kim HS et al. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 2009;24: S50-56.
15. Breimer LH, Mikhailidis DP. Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target? Curr Pharm Des 2011;17: 3644-55.
16. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2011-2012. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2012.
17. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2009-2010. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2010.
18. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2007-2008. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
19. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2005-2006. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2006.
20. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2003-2004. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2004.
21. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 2001-2002. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2002.
22. National Center for Health Statistics. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data 1999-2000. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2000.
23. Perloff D, Grim C, Flack J et al. Human blood pressure determination by sphygmomanometry. Circulation 1993;88: 2460-70.
24. National Center for Health Statistics. Centers for Disease Control and Prevention. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey questionnaire, examination protocol and laboratory protocol. Hyattsville, MD: United States Department of Health and Human Services, Centers for Disease Control and Prevention, 1999-2012.
25. Allison PD. Missing data. In: Millsap RE, Maydeu-Olivares A (eds). The SAGE Handbook of Quantitative Methods in Psychology. Thousand Oaks, CA: Sage Publications, 2009.
26. Sterne JA, White IR, Carlin JB et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338: b2393.
27. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30: 377-99.
28. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. StatMed 1999;18: 681-94.
29. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. StatMed 2005;24: 2911-35.
30. Royston P. Multiple imputation of missing values: Further update of ice, with an emphasis on interval censoring. Stata J 2017;7: 445-64.
31. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10: 37-48.
32. Pearl J. Causal diagrams and the identification of causal effects. In: Causality: Models, Reasoning, and Inference. New York, NY: Cambridge University Press, 2000.
33. Shpitser I, VanderWeele T, Robins JM. On the validity of covariate adjustment for estimating causal effects. In: Proceedings of the Twenty Sixth Conference on Uncertainty in Artificial Intelligence (UAI-10). Corvallis, OR: AUAI Press, 2012.
34. Shrier I, Platt R. Reducing bias through directed acyclic graphs. BMC Med Res Methodol 2008;8: 70.
35. Textor J, Liskiewicz M. Adjustment criteria in causal diagrams: an algorithmic perspective. Proceedings of the 27th Conference on Uncertainty in Artificial Intelligence. Corvallis, OR: AUAI Press, 2011.
36. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analysing causal diagrams. Epidemiology 2011;22: 745.
37. Elwert F. Graphical causal models. In: Morgan SL (ed). Handbook of Causal Analysis for Social Research. New York, NY: Springer; 2013.
38. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19: 857-61.
39. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290: 2945-51.
40. Sesso HD, Cook NR, Buring JE, Manson JE, Gaziano JM. Alcohol consumption and the risk of hypertension in women and men. Hypertension 2008;51: 1080-87.
41. Cohen S, Schwartz JE, Epel E, Kirschbaum C, Sidney S, Seeman T. Socioeconomic status, race, and diurnal cortisol decline in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. PsychosomMed 2006;68: 41-50.
42. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007;49: 432-38.
43. Block JP, He Y, Zaslavsky AM, Ding L, Ayanian JZ. Psychosocial stress and change in weight among US adults. Am J Epidemiol 2009;170: 181-92.
44. Carlson SA, Densmore D, Fulton JE, Yore MM, Kohl HW. Differences in physical activity prevalence and trends from 3 US surveillance systems: NHIS, NHANES, and BRFSS. J Phys Act Health 2009;6(Suppl 1): S18-27.
45. King AC, Castro C, Wilcox S, Eyler AA, Sallis JF, Brownson RC. Personal and environmental factors associated with physical inactivity among different racial-ethnic groups of U.S. middle-aged and older-aged women. Health Psychol 2000;19: 354-64.
46. Høstmark AT, Tomten SE, Berg JE. Serum albumin and blood pressure: a population-based, cross-sectional study. J Hypertens 2005;23: 725-30.
47. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45: 28-33.
48. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Care Res 2004;51: 1023-29.
49. Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010;52: 578-89.
50. Kudielka BM, Buske-Kirschbaum A, Hellhammer DH Kirschbaum C. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 2004;29: 83-98.
51. Spruill T. Chronic psychosocial stress and hypertension. Curr Hypertens Rep 2010;12: 10-16.
52. Hernán MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15: 615-25.
53. Groenwold RHH, Moons KGM, Peelen LM, Knol MJ, Hoes AW. Reporting of treatment effects from randomized trials: A plea for multivariable risk ratios. Contemp Clin Trials 2011;32: 399-402.
54. Bautista LE. High blood pressure. In: Remington PL, Brownson RC, Wegner MV (eds). Chronic Disease Epidemiology and Control. 3rd edn. Washington, DC: American Public Health Association, 2010.
55. Greenland S. Comment: Cautions in the use of preliminary-test estimators. Stat Med 1989;8: 669-73.
56. Herrera VM, Casas JP, Miranda JJ et al. Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease. Int J Obes (Lond) 2009;33: 568-76.
57. StataCorp LP. Stata Multiple-Imputation Reference Manual: Release 13. College Station, TX: Stata Press, 2013.
58. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Applied Logistic Regression. New York, NY: John Wiley, 2000.
59. Pregibon D. Logistic regression diagnostics. Ann Stat 1981;9: 705-24.
60. Cook RD. Detection of influential observation in linear regression. Technometrics 2000;42: 65-68.
61. Bollen KA, Jackman RW. Regression diagnostics an expository treatment of outliers and influential cases. Sociol Method Res 1985;13: 510-42.
62. D'Agostino RB. Propensity scores in cardiovascular research. Circulation 2007;115: 2340-43.
63. Ichino A, Mealli F, Nannicini T. From temporary help jobs to permanent employment: what can we learn from matching estimators and their sensitivity? J Appl Econom 2008;23: 305-27.
64. Nannicini T. Simulation-based sensitivity analysis for matching estimators. Stata J 2007;7: 334-50.
65. Perneger TV, Nieto F, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine: Results from the 'CLUE' study and the ARIC study. JAMA 1993;269: 488-93.
66. Spirtes P. The limits of causal inference from observational data. 1997. http://www.hss.cmu.edu/philosophy/facultyspirtes.php (18 September 2014, date last accessed).
67. Spirtes P, Glymur CN, Scheines R. Causation, Prediction, and Search. Cambridge, MA: MIT Press, 2000.
68. Ajja R, Lee D-c, Sui X, Church TS, Steven NB. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol 2011;108: 1438-42.
69. Fulks M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J Insur Med 2008;41: 49-53.
70. Temme EM, Zhang J, Schouten E, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001;12: 887-94.
71. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360: 1903-13.
72. Greenland S. Quantifying biases in causal models: Classical confounding vs collider-stratification bias. Epidemiology 2003;14: 300-06.
73. Cole SR, Platt RW, Schisterman EF et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol 2009;39: 417-20.
74. McArdle P, Whitcomb B, Tanner K, Mitchell B, Shuldiner A, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012;12: 16.
75. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161: 1183-92.
76. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008;198: 1-11.
77. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008;199: 390-96.
78. Vi'tek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. In: Makowski G (ed). Advances in Clinical Chemistry. 2007. www.elsevier.com/books/book-series/advances-in-clinicalchemistry.
79. Ohnaka K, Kono S. Bilirubin, cardiovascular diseases and cancer: epidemiological perspectives. Expert Rev Endocrinol Metab 2010;5: 891-904.
80. Rodrigo R, González J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 2011;34: 431-40.
81. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008;31: S181-84.
82. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327: 524-26.
83. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol Cell Physiol 1996;40: C1424.
84. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function. Biochem Biophys Res Commun 1999;263: 681-84.
85. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111: 1201-09.
86. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87: 9383-87.
87. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320: 454-56.
88. Bouloumie A, Bauersachs J, Linz W et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 1997;30: 934-41.
89. Quyyumi AA, Patel RS. Endothelial dysfunction and hypertension: cause or effect? Hypertension 2010;55: 1092-94.
90. Shimbo D, Muntner P, Mann D et al. Endothelial dysfunction and the risk of hypertension: The Multi-Ethnic Study of Atherosclerosis. Hypertension 2010;55: 1210-16.
91. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 2004;44: 1636-40.
92. Barañano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: A major physiologic cytoprotectant. Proc Natl Acad Sci U SA 2002;99: 16093-98.
93. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987;84: 5918-22.
94. Gopinathan V, Miller NJ, Milner AD, Rice-Evans CA. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett 1994;349: 197-200.
95. Jiang F, Roberts SJ, Datla S, Dusting GJ. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006;48: 950-57.
96. Lanone S, Bloc S, Foresti R et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005;19: 1890-92.
97. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003;285: R277-97.
98. McCarty MF. ''Iatrogenic Gilbert syndrome'' - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007;69: 974-94.
99. Erdogan D, Gullu H, Yildirim E et al. Low serum bilirubin levels are independently and inversely related to impaired flowmediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006;184: 431-37.
100. O'Malley SS, Wu R, Mayne ST, Jatlow PI. Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 2014;16: 1145-49.
101. Swift DL, Johannsen NM, Earnest CP, Blair SN, Church TS. Effect of different doses of aerobic exercise training on total bilirubin levels. Med Sci Sports Exerc 2012;44: 569-74.
102. Andersson C, Weeke P, Fosbøl EL et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular highrisk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009;58: 1109-15.
103. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60: 79-127.
104. Soares MP, Bach FH. Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med 2009;15: 50-58.
105. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K-i, Tallman MN, Brouwer KLR. Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 2006;27: 447-86.
106. Kris-Etherton PM, Lichtenstein AH, Howard BV et al. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004;110: 637-41.
107. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 2008;101: S14-19.